Management of ASCUS with Negative HPV

Risk Stratification

Women with HPV-negative ASCUS have a low but measurable risk of precancer, with a 5-year CIN3+ risk of 0.48%, which is higher than after a completely negative cotest but similar to a negative Pap test alone, according to the American Cancer Society 2

For a 52-year-old woman with ASCUS and negative HPV testing, repeat HPV testing in 3 years is recommended, as per the Centers for Disease Control and Prevention guidelines 1
The follow-up interval of 3 years represents an update from older guidelines that recommended 5-year follow-up, based on expanded data analyzing over 1.1 million women, as reported by the American Cancer Society 2
If HPV test remains negative and cytology is normal at the 3-year follow-up visit: return to routine age-based screening, as recommended by the Centers for Disease Control and Prevention 1
If HPV test is positive OR cytology shows abnormalities at the 3-year follow-up visit: refer to colposcopy, according to the Centers for Disease Control and Prevention guidelines 1

A patient with HPV-negative ASCUS cannot exit screening at age 65 based on this result, as per the National Comprehensive Cancer Network guidelines 5
The patient must continue surveillance until achieving either 2 consecutive negative cotests or 3 consecutive negative Pap tests before discontinuing screening, as recommended by the National Comprehensive Cancer Network 5
Women ages 60-65 with HPV-negative ASCUS showed disproportionately higher cancer risk compared to those with negative cotests, despite low dysplasia risk, according to the National Comprehensive Cancer Network 5

The 2019 ASCCP risk-based management guidelines prioritize management based on CIN3+ risk rather than specific test results, using clinical action thresholds to generate personalized recommendations, as reported by the Centers for Disease Control and Prevention 1
The shift from 5-year to 3-year follow-up for HPV-negative ASCUS reflects the principle of "equal management of equal risks", according to the American Cancer Society 2